GHRP-6 Research Guide: GHS-R1a and CD36 Mechanism, Preclinical Literature, and Verification

Almost every synthetic growth hormone secretagogue in a modern research library traces back to a single hexapeptide characterized in the early 1980s. GHRP-6 — growth hormone-releasing peptide-6 — is that founding molecule: the first synthetic peptide shown to release growth hormone through a receptor system entirely distinct from growth hormone-releasing hormone. It is the parent compound from which stabilized analogs such as hexarelin were later engineered, and its discovery is what eventually led investigators to clone the ghrelin receptor and, years later, to identify ghrelin itself. For a research group building around the somatotropic axis and the ghrelin/GHS-R1a system, GHRP-6 is the reference point — the ligand every subsequent secretagogue is measured against. This guide surveys GHRP-6 at the molecular and preclinical level: what it is, how it engages its two receptors, what the primary literature actually reports, and how a laboratory should evaluate the material it sources.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes.

Section 1 — Molecular Profile

GHRP-6 is a fully synthetic hexapeptide — six amino acids — generated by Cyril Bowers and Frank Momany through a combination of conformational energy calculations and iterative assessment of growth hormone-releasing activity. It was originally derived from work on met-enkephalin analogs but bears no functional relationship to opioid signaling; its defining property is selective stimulation of growth hormone release.

GHRP-6

• CAS number: 87616-84-0 (free base); 145177-42-0 (acetate salt)
• Molecular formula: C46H56N12O6
• Molecular weight: approximately 873.0 g/mol (873 Da)
• Length: 6 amino acids (hexapeptide)
• Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (also written [His1, Lys6] GHRP)
• Class: synthetic growth hormone secretagogue; peptidyl ghrelin-receptor (GHS-R1a) agonist; CD36 ligand

Two structural features define the molecule and matter directly for laboratory handling. First, GHRP-6 carries two D-amino acids — D-tryptophan at position two and D-phenylalanine at position five. Substituting the naturally occurring L-form for the mirror-image D-form is a classic strategy for making a short peptide more resistant to the peptidases that recognize native L-peptide bonds, and it is central to why this hexapeptide retains activity where a native sequence would be rapidly degraded. Second, the C-terminal amide (the “-NH2” that closes the sequence) removes the free carboxyl group, a common stabilizing feature across the secretagogue peptide family. GHRP-6 is typically supplied as an acetate salt in lyophilized form; the counterion is why the acetate carries its own distinct CAS number and why quantitative work should reference the salt form actually present in the vial. These are precisely the details that determine assay reproducibility and that a lot-specific analytical file exists to confirm.

Section 2 — Mechanism

GHRP-6’s mechanism is best described at the level of its two receptors, because the two-receptor profile is what makes it more than a simple growth hormone stimulus.

The first and primary receptor is the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same G-protein-coupled receptor later shown to be the endogenous target of the hormone ghrelin. Historically the sequence is worth noting: GHRP-6 existed as a pharmacological tool for more than a decade before its receptor was identified. Howard and colleagues cloned GHS-R from pituitary and hypothalamus in 1996 specifically as the target of synthetic secretagogues like GHRP-6, and only in 1999 was ghrelin discovered as the natural ligand for that same receptor. In other words, GHRP-6 is the synthetic probe that led biology to an entire endogenous signaling system. On binding, GHS-R1a couples preferentially to the Gq/11 class of G-proteins, activating phospholipase C, generating inositol trisphosphate, and driving a rise in intracellular calcium in the somatotroph cells of the anterior pituitary. That calcium signal is the proximate trigger for growth hormone secretion. Mechanistic work established that GHRP-6 acts at more than one node — a direct action on the pituitary, an indirect action involving release of growth hormone-releasing hormone (GHRH), and a functional opposition to the inhibitory tone of somatostatin — so it engages the axis by a route distinct from a GHRH analog such as sermorelin or tesamorelin.

The second receptor is CD36, a multifunctional scavenger receptor expressed on cardiomyocytes, microvascular endothelial cells, and macrophages. This is where GHRP-6 departs from a pure growth-hormone stimulus. Affinity-purification work identified CD36 as a binding partner for growth hormone-releasing peptides in cardiac and vascular tissue, and this interaction is thought to mediate a set of cytoprotective and cardiovascular effects in model systems that are separable from — and do not depend on — systemic growth hormone release. Binding of GHRP-6 to CD36 has been linked in preclinical work to activation of pro-survival signaling such as the PI3K/AKT pathway, reduced reactive-oxygen-species spillover, and downregulation of apoptotic drivers.

For research design, the practical takeaways are these. GHRP-6 is the prototypical peptidyl GHS-R1a agonist, useful as the founding reference ligand for the Gq/calcium arm of ghrelin-receptor pharmacology, distinct from the Gαs/cAMP GHRH-receptor route. And its CD36 activity means it is studied as a probe of a growth-hormone-independent signaling pathway across several parenchymal tissue models. Everything in this article stays at exactly that level: receptor binding, second-messenger generation, and cell- and tissue-model responses.

Section 3 — Preclinical Research Data

The preclinical dataset around GHRP-6 clusters into two themes that mirror its two receptors.

On the growth hormone side, the foundational pharmacology characterized GHRP-6 as a hexapeptide that elicits a dose-related release of growth hormone in vitro and in vivo without concomitant release of luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, or prolactin — the selectivity that made it a landmark tool compound. Radioligand studies then demonstrated saturable, specific binding to defined hypothalamic and pituitary sites, providing early evidence for the dedicated receptor that would later be cloned as GHS-R1a. Together these established GHRP-6 as the archetype of the synthetic secretagogue class and the template from which more potent stabilized analogs, including hexarelin, were subsequently designed.

On the cytoprotective side — the more distinctive body of more recent work — GHRP-6 has been examined repeatedly in isolated-tissue and whole-animal injury models, largely attributed to its CD36 activity. In acute myocardial infarction models, GHRP-6 was reported to prevent oxidant cytotoxicity and reduce myocardial necrosis, with preserved wall thickness and reduced infarct mass relative to vehicle controls in rodent studies. More recent mechanistic work in a permanent coronary-ligation model reported that GHRP-6 attenuated post-infarct ventricular remodeling and systolic dysfunction, consistent with a role in limiting fibrotic remodeling after injury. Beyond the heart, the cytoprotective signature described in review literature extends across cardiac, neuronal, gastrointestinal, and hepatic cell models — a comparatively broad spectrum of parenchymal-tissue protection for a single hexapeptide, and one investigators have linked to the compound’s antioxidant and anti-apoptotic signaling through CD36.

Across these datasets the recurring research themes are selectivity and receptor duality: GHRP-6’s clean growth-hormone-releasing profile is what made it the founding tool compound, and its CD36 binding is what gives it a cytoprotection literature that a pure GHRH analog simply does not have. All of the outcomes above are cell-model and animal-model findings, cited here as preclinical research context only.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for a GHRP-6 research library:

• Bowers CY, Momany FA, Reynolds GA, Hong A. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology, 1984; 114(5):1537–1545 (PMID 6714155).
• Codd EE, et al. “Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites.” Neuropharmacology, 1989 (PMID 2812284).
• Howard AD, et al. “A receptor in pituitary and hypothalamus that functions in growth hormone release.” Science, 1996; 273(5277):974–977 (PMID 8688086).
• Berlanga-Acosta J, et al. “Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.” Clinical Medicine Insights: Cardiology, 2017 (PMID 28469508).
• Proulx CD, et al. “Synthesis and Biomedical Potential of Azapeptide Modulators of the Cluster of Differentiation 36 Receptor (CD36).” Biomedicines, 2020 (PMID 32717955).
• Berlanga-Acosta J, et al. “Growth hormone releasing peptide-6 (GHRP-6) and other related secretagogue synthetic peptides: A mine of medical potentialities for unmet medical needs.” Integrative Molecular Medicine, 2016.
• “Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.” Pharmaceuticals (Basel), 2026.

These references trace GHRP-6 from its original growth-hormone-releasing characterization, through the receptor-binding work and the cloning of GHS-R1a, to the cell- and animal-model studies that define its CD36-mediated cytoprotective profile — the primary literature a research group needs to design and interpret in-vitro work.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, GHRP-6 is studied for a set of overlapping, model-system purposes:

• GHS-R1a agonist reference ligand: calcium-flux, inositol-phosphate, and reporter assays in ghrelin-receptor-expressing cell lines, using GHRP-6 as the founding peptidyl comparator against ghrelin and against stabilized analogs such as hexarelin.
• CD36 pathway probe: cardiomyocyte, endothelial, neuronal, and hepatic model systems used to study growth-hormone-independent signaling through the CD36 scavenger receptor, isolating tissue responses from pituitary growth hormone release.
• Receptor-selectivity work: contrasting the Gq/calcium GHS-R1a route that GHRP-6 engages with the Gαs/cAMP GHRH-receptor route engaged by GHRH analogs, making GHRP-6 a foundational counterpart ligand for mapping GH-axis pharmacology.
• Structure-activity benchmarking: using GHRP-6 as the unmodified parent against which the peptidase-resistance and potency gains of engineered analogs (for example hexarelin’s 2-methyl-tryptophan substitution) are measured.
• Analytical method development: GHRP-6 and its GHRP-family relatives cluster in sequence and mass, making them demanding test articles for validating LC-MS identity workflows and HPLC separation of closely related secretagogue peptides.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade GHRP-6 is supplied as a research chemical rather than a finished pharmaceutical preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage figure — important even for a short hexapeptide, where deletion sequences and diastereomer impurities can arise from the two D-amino-acid positions.
• LC-MS or MS identity confirmation of the ~873 Da target mass, essential in a family where the GHRP-class secretagogues cluster closely in mass and the D-configuration must be confirmed rather than assumed.
• Endotoxin and heavy-metal testing for lyophilized material intended for cell-based work.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, GHRP-6 is one of the more established and widely synthesized research secretagogues, which means the range of quality on offer is unusually wide — from genuinely well-characterized, fully documented material to under-characterized product sold on price alone. Cost signals nothing about identity or purity; only third-party analytical data does. A low price attached to no verifiable COA is a red flag, not a bargain, and for a peptide as commonly counterfeited and adulterated as GHRP-6, orthogonal identity confirmation is the difference between a usable reference ligand and an unknown mixture.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a hexapeptide like GHRP-6, orthogonal identity testing is not optional. It is the only way to confirm that a vial labeled as GHRP-6 contains the correct sequence carrying its two D-amino-acid residues — rather than a truncated deletion sequence, a closely related GHRP-family analog, or a diastereomer that shares part of its mass. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/ghrp-6/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.